Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of penehyclidine hydrochloride in the treatment of pulmonary arterial microthromboembolism caused by septic shock

A technology for penehyclidine hydrochloride and septic shock, which is applied in the treatment of pulmonary arterial microthrombosis caused by septic shock. , the problem of poor clinical application

Active Publication Date: 2015-10-28
JINZHOU AHON PHARM CO LTD
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0017] The above two patents and documents both disclose the application of penehyclidine hydrochloride in the treatment of endotoxic shock disease drugs, but there is no further study on the pulmonary microthromboembolism caused by septic shock, and the combination with clinical symptoms Not strong, clinical application is not highly targeted, thus affecting the applicator's judgment on the scope of application

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of penehyclidine hydrochloride in the treatment of pulmonary arterial microthromboembolism caused by septic shock
  • Application of penehyclidine hydrochloride in the treatment of pulmonary arterial microthromboembolism caused by septic shock

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0024] The substantive content of the present invention will be further described in detail below in conjunction with specific embodiments.

[0025] 1.1 Experimental materials

[0026] 1.1.1 Experimental drugs

[0027] Penehyclidine Hydrochloride Injection (Changtuoning): Anticholinergic, anti-shock treatment. Specifications: 1ml: 1mg. Provided by Chengdu Lisite Pharmaceutical Co., Ltd., the batch number is 111201. Clinical intravenous injection, the first dose is 6 mg, and then 2 mg is given every 12 hours according to the situation for maintenance, and the total dose is 10 mg / d.

[0028] The reference adult clinical dosage in this experiment is 0.1667 mg / kg·d (10 mg / 60kg·d), according to the conversion formula of human and animal dosage A=kW 2 / 3 / 10000 for calculation, the dose for rabbits is 0.3632 mg / kg·d, the drug is diluted with normal saline, the concentration is 0.018162 mg / ml, and the administration volume is 10ml / kg.

[0029] Pentobarbital sodium salt (Pentobarb...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of penehyclidine hydrochloride in treatment of tiny thromboembolism of pulmonary artery caused by an infectious shock. Microcirculation can be effectively improved, tissue perfusion is increased, and especially, the penehyclidine hydrochloride has a significant effect on the tiny thromboembolism of pulmonary artery caused by the infectious shock.

Description

technical field [0001] The invention belongs to the field of medicines, and in particular relates to the application of penehyclidine hydrochloride in the treatment of pulmonary arterial microthromboembolism caused by septic shock. Background technique [0002] Penehyclidine hydrochloride, English name Penehyclidine Hydrochloride, chemical name 3-(2-cyclopentyl-2-hydroxy-2-phenylethoxy)quinuclidine hydrochloride, molecular formula C 20 h 29 NO 2 • HCl, molecular weight 351.92. [0003] Penehyclidine hydrochloride is a new type of anticholinergic drug with selective M 1 , M 3 and N 1 , N 2 Receptor antagonism, has a strong anticholinergic effect on the central and peripheral, and has a strong anticholinergic effect on M 2 The receptor has no obvious effect, which can effectively avoid the tachycardia caused by atropine lack of M receptor subtype selectivity and block the presynaptic membrane M 2 Receptor regulation function, and long efficacy and less side effects, it...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/439A61P7/02
Inventor 黄绍渊张浩樊昊梁慧容
Owner JINZHOU AHON PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com